Small molecule inhibitors of the cyclin kinase inhibitor, p21, specifically affect p21 levels and can potentially be used in treating cancer.
Cyclin kinase inhibitor p21 promotes cell survival by preventing the apoptosis of cells. Thus, this protein is the cancer cell’s method of defeating attempts to kill it, as by chemotherapy, a situation which is clearly harmful for the cancer patient.
Using drug design, researchers at University of California have discovered several specific inhibitors of p21 that are more stable and more effective than the previously discovered small molecule p21 inhibitors. Inhibiting the levels of p21 diminishes its anti-apoptotic effect on cells and makes cells more amenable to cell death.
|United States Of America||Issued Patent||10,449,182||10/22/2019||2012-486|
p21 inhibitors, cancer therapy, small molecule cancer therapy, kidney cancer, cancer